A bill commonly known as “Right to Try,” or S.204, appears to be a step in the right direction for expanding access to treatment for terminally ill patients who have exhausted all other options.
The investigational oncolytic immunotherapy CG0070 produced an overall 30% complete response rate at 12 months for patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
“We believe that our study underscores the importance of improving dissemination of the guidelines and their implementation and uptake in practice,” says researcher Nikhil Waingankar, MD, MSHP.
Advanced-practice providers can report services incident to an MD under a few circumstances.
Noteworthy minimally invasive surgery research from AUA 2018 also included topics such as robot-assisted versus open radical cystectomy as well as minimally invasive retroperitoneal lymph node dissection in men with testis cancer.
"Despite the potential benefits (fewer biopsies, less cost), the proposed approach to cancer detection and biopsy—that can miss 16%-40% of existing csPCa—may be difficult to justify for all patients," writes Badar M. Mian, MD.
The AUA 2018 take-home messages in outcomes also covered topics such as environmental exposures and bladder cancer and onabotulinumtoxinA (Botox) treatment for patients with overactive bladder.
Contrast-enhanced ultrasound for detecting renal cell carcinoma recurrence following albation and new protocols for low-dose computed tomography in stone patients were among the other research highlights in imaging at the AUA annual meeting.
Other penile/urethral cancer highlights from AUA 2018 included analyses of fludeoxyglucose positron emission tomography-computed tomography and the Pl3K-AKT-mTOR pathway.